Adrian M Senderowicz

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas
    Adrian M Senderowicz
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Oncology (Williston Park) 21:1696-706; discussion 1706-9, 1712, 1715. 2007
  2. ncbi request reprint Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms
    Adrian M Senderowicz
    Molecular Therapeutics Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Building 30, Room 211, Bethesda, MD 20892 4340, USA
    Cancer Chemother Pharmacol 52:S61-73. 2003
  3. ncbi request reprint Inhibitors of cyclin-dependent kinase modulators for cancer therapy
    Adrian M Senderowicz
    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bldg 10, Room B3 B6, Bethesda, MD 20892, USA
    Prog Drug Res 63:183-206. 2005

Detail Information

Publications3

  1. ncbi request reprint Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas
    Adrian M Senderowicz
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Oncology (Williston Park) 21:1696-706; discussion 1706-9, 1712, 1715. 2007
    ..Physicians and patients now have a new option for the treatment of locally advanced/metastatic adenocarcinoma of the pancreas...
  2. ncbi request reprint Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms
    Adrian M Senderowicz
    Molecular Therapeutics Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Building 30, Room 211, Bethesda, MD 20892 4340, USA
    Cancer Chemother Pharmacol 52:S61-73. 2003
    ..Despite these caveats, we feel that CDKs are sensible targets for cancer therapy and that there are several small-molecule CDK modulators in clinical trials with encouraging results...
  3. ncbi request reprint Inhibitors of cyclin-dependent kinase modulators for cancer therapy
    Adrian M Senderowicz
    Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bldg 10, Room B3 B6, Bethesda, MD 20892, USA
    Prog Drug Res 63:183-206. 2005
    ....